ALZFORUM4d
Lecanemab Tops Other Antibodies at Binding Soluble Aβ Aggregates
Lecanemab Favors Early Aggregates. Fluorescently labeled lecanemab (green) bound most strongly to soluble Aβ aggregates ...
Why thousands of dementia sufferers are being denied the new miracle drug
In late 2022, the results of a groundbreaking stage-three trial for a ‘miracle’ new Alzheimer’s drug, lecanemab, were hailed ...
Alzheimer’s wonder drug faces NHS block over cost
The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday.Regulators are expected to declare ...
The American Journal of Managed Care12d
Discarded Lecanemab Leads to Medicare Drug Waste of Up to $336 Million
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
The Financial Express1d
Lilly’s donanemab could bring new hope to Alzheimer’s patients in Australia following lecanemab rejection: GlobalData
There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.
Smaller vial size for Alzheimer's drug could save Medicare hundreds of millions per year
Medicare could save up to 74% of the money lost from discarded Alzheimer's drug lecanemab by the simple introduction of a new ...
Monthly Prescribing Reference6d
Annual Wasteful Spending on Lecanemab Estimated at $133 to $336 Million
Adding 75mg vial size would achieve greatest reduction in waste, representing annual savings of $99 million. HealthDay News — Annual wasteful spending on discarded lecanemab is anticipated to ...
openaccessgovernment3d
Donanemab: NHS rejects second promising drug for Alzheimer’s
A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...
Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in ...
Eisai will request reconsideration of initial decision for lecanemab in Australia
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to ...
Yahoo Finance10d
Eisai will request reconsideration of initial decision for lecanemab in Australia
STOCKHOLM, Oct. 16, 2024 /PRNewswire/ --BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public ...